Aflibercept‑Yszy 2 mg/0.05 mL Suppliers & Bulk Manufacturers
Available Forms: Injectable solution
Available Strengths: 2 mg/0.05 mL
Reference Brands: Eylea(US & EU); Opuviz biosimilar to biosimilar to Eylea
Category: Opthalmology
Opuviz, a biosimilar of Eylea, inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye. It treats conditions like age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Benefits include similar efficacy, potentially lower costs, and improved access to vital eye disease treatments.
Product Description:
Opuviz, a biosimilar of Eylea, is regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality per GMP standards. In the US, FDA approval involves comprehensive clinical validation, safety assessments, and comparability data. In the EU, CE marking certifies conformity with MDR standards for biosimilars. These products undergo validation, stability testing, and audits, with detailed documentation including safety profiles, clinical data, and manufacturing practices. For licensing procedures, approved dossiers, and latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to safe, effective ophthalmic biosimilars supporting effective eye disease management worldwide.
Aflibercept‑Yszy — third party manufacturing & bulk supply
Aflibercept‑Yszy 2 mg/0.05 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Aflibercept‑Yszy listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Aflibercept‑Yszy →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Aflibercept‑yszy is used to treat eye conditions involving abnormal blood vessel growth and fluid leakage in the retina, including wet age‑related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). It works by inhibiting vascular endothelial growth factor (VEGF) to help slow vision loss and improve retinal function.
The active ingredient is aflibercept, a recombinant fusion protein that binds VEGF‑A, VEGF‑B, and placental growth factor (PlGF). It is formulated as a sterile solution for intravitreal injection.
The trade name is Aflibercept‑yszy.
Aflibercept‑yszy is manufactured by licensed biopharmaceutical companies producing approved biosimilars according to regional regulatory standards.
The generic name is Aflibercept.
The brand name is Aflibercept‑yszy.
It is manufactured in GMP‑certified biopharmaceutical facilities to ensure quality, sterility, and regulatory compliance for intravitreal use.
Related Products
Artificial Tears
Strength:
0.3% to 1%
Form: Eye Drops/ Eye Gel/ Eye ointment
Reference Brands: Refresh Tears (USA/LATAM), Hylo-Tear (EU), Refresh Liquigel (India)
View Details
Tetrahydrozoline Hydrochloride
Strength:
0.05%
Form: Eye Drops
Reference Brands: Visine (USA/EU / LATAM), Ocuvis (India)
View Details
Quick Response Guaranteed | Verified Suppliers
